Monitor for regulatory approval updates from NIT, as commercial supply and revenue for Emmaus are contingent on this milestone. Absent approval, no material financial impact will occur.
Price Chart
Executive Summary
Emmaus Life Sciences entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT) to supply Endari (L-glutamine) for sickle cell disease in the U.S. and Canada, contingent on NIT obtaining regulatory approval. Emmaus will supply the product at cost plus a double-digit margin, but the deal is not guaranteed as the effective date depends on regulatory milestones and could terminate by October 1, 2026 if not met.
Key Financial Metrics
Key Facts
- Emmaus Life Sciences (EMMA) entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT) on March 2, 2026
- The agreement is contingent on NIT obtaining regulatory approvals to market and distribute Endari in the U.S. and Canada
- Emmaus will supply Endari to NIT at cost of production plus a double-digit percentage margin
- The License Agreement may be terminated by either party if the Effective Date does not occur by October 1, 2026, unless due to Emmaus' wrongful acts
- The supply agreement supports a prior license deal where NIT gained exclusive rights to market, sell, and distribute Endari in the U.S. and Canada for sickle cell disease
Financial Impact
Potential future revenue stream based on cost-plus margin, but no guaranteed financial impact due to regulatory contingencies
Risk Factors
- Deal may not close if NIT fails to obtain required regulatory approvals
- No assurance of revenue generation if the Effective Date does not occur by October 1, 2026
- Dependence on NIT's commercial execution in the U.S. and Canadian markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-023644 |
| Document: 0001213900-26-023644-index-headers.html | 0001213900-26-023644 |
| Document: 0001213900-26-023644-index.html | 0001213900-26-023644 |
| Document: 0001213900-26-023644.txt | 0001213900-26-023644 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 8-K | $0.0115 | awaiting T+60 | — | $0.0460 (+300.00%) |
Apr 17, 2026 27w ago | 8-K | $0.009100 $0.0115 | ▲ +25.93% | ▲ +19.16% | $0.0460 (+405.49%) |
Mar 31, 2026 29w ago | 8-K | $0.0150 $0.0100 | ▲ +33.33% | ▲ +45.72% | $0.0460 (−206.67%) |
Mar 4, 2026 33w ago | 8-K | $0.0145 $0.009600 | ▼ −33.79% | ▼ −45.09% | $0.0460 (+217.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers